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Abstract
Background: Coronary artery disease (CAD) dominates in the contemporary world among the causes of left ventricular dysfunction (LVD). Prognosis 
of survival and the course of heart failure (HF) are worse in patients with CAD than in many kinds of non-ischemic cardiomyopathy. Development of 
cardiac surgery technologies and formation of the relevant evidence base have significantly expanded the role of revascularization in patients with CAD 
and reduced left ventricular ejection fraction (LVEF). The possibility and expediency of coronary artery bypass grafting (CABG) for improving left 
ventricular ejection fraction (LVEF), clinical course of HF and survival are evidence-based. Stenting is less effective than coronary artery bypass grafting 
(CABG) regarding the influence on primary endpoints but improves the quality of life of patients with CAD and ischemic LVD. 
Conclusions: In patients with ischemic LVD, surgical revascularization can ensure an improvement in the pumping function of the heart, provided 
there is a sufficient amount of viable myocardium. From the standpoint of evidence-based medicine, the effectiveness of CABG surgery in patients with 
multivessel lesion of the coronary bed and LVD has been proven for correction LVEF, improvement of the course of the disease and prediction of survival 
compared with the optimal drug therapy. Percutaneous intervention is inferior to surgical revascularization in terms of its effect on endpoints, but it can 
make an improvement in the quality of life of patients with ischemic LVD. Evaluation of myocardial viability may be of additional importance for the 
decision on the feasibility of CABG in the presence of multivessel coronary artery disease combined with a sharp decrease in LVEF.
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Introduction
Heart failure (HF) combined with a reduced left ven-
tricular ejection fraction (LVEF) determines an unfavor-
able prognosis for survival and is associated with frequent 
hospitalizations due to decompensation of the blood circu-
lation. According to the Framingham study, the average life 
expectancy of patients with LVEF is less than 20% and clini-
cal manifestations of HF is 1.7 years in men and 3.2 years in 
women [22]. Coronary atherosclerosis prevails among the 
causes of left ventricular systolic dysfunction (LVSD), and 
the survival prognosis in patients with coronary artery dis-
ease (CAD) is worse than in many types of non-ischemic 
cardiomyopathy [11]. At the same time, unlike many other 
causes of left ventricular dysfunction (LVD), patients with 
CAD potentially have a chance of recovery of myocardial 
contractile function after revascularization. 
Multivessel coronary artery disease and concomitant 
diabetes mellitus are often found in patients with reduced 
LVEF, presenting strong arguments in favor of surgical 
myocardial revascularization. On the other hand, back-
ground LVD is associated with a certain increase in the 
risk of “major” cardiac surgeries and was even considered 
a limitation for their implementation. The first attempts 
of surgical treatment of patients with CAD and LVD were 
made almost half a century ago [27]. Initially, coronary ar-
tery bypass grafting (CABG) surgery in patients with LVD 
resulted in high mortality (from 1.4 to 18.6%) and multi-
ple postoperative complications [35]. However, due to the 
rapid development of cardiac surgery technologies and for-
mation of an appropriate evidence base, the role of revas-
cularization in patients with ischemic LVD has gradually 
expanded [17, 26, 30]. Despite this, according to a recent 
review of clinical practice, the incidence of coronaroven-
triculography (CVG) in patients with newly diagnosed HF 
is still insufficient [9]. Moreover, a number of questions re-
main unanswered regarding the selection of patients and 
monitoring the effectiveness of revascularization, in partic-
ular regarding the possibility of LVD correction after sur-
gery. This review summarizes the current understanding of 
the possibilities and the choice of the optimal method of 
revascularization in patients with ischemic LVD and signs 
of HF.
Ischemic cardiomyopathy and myocardial viability
In 1970, G. Burch offered the term “ischemic cardio-
myopathy”, referring to the course of CAD with multiple 
lesions of the coronary arteries, increased ventricular heart 
sizes and clinical symptoms of congestive HF [7]. The cause 
of myocardial dysfunction in such patients is the decreased 
blood flow in the subendocardial zones. Progressive de-
crease in the availability of high-energy compounds and 
acidosis cause increased myocardial rigidity, while volume 
overload of the heart causes dilatation of its chambers. An 
important feature of ischemic cardiomyopathy is the po-
tential reversibility of regional and global abnormalities in 
LV function.
The term “viable myocardium” refers to ischemic heart 
muscle with a reduced functional capacity which does not 
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have, or has a limited amount of scar tissue, which in turn 
determines the potential possibility of restoring its func-
tion after revascularization. With LVD progression myo-
cardial viability is ensured due to a significant limitation 
of its energy expenditure, that is, the state of hibernation. 
There should be a distinction between hibernating and 
“stunned myocardium”, the latter being a condition of post-
ischemic LVD, which persists after reperfusion, despite the 
restoration of coronary blood flow [12]. 
Determining the percentage of viable myocardium us-
ing stress echocardiography, perfusion scintigraphy or 
magnetic resonance imaging with contrast enhancement 
may be useful in candidates for revascularization or heart 
transplantation after undergoing common myocardial in-
farction with left ventricular aneurysm, as well as in pa-
tients with CAD and LVEF less than 35% in the absence of a 
large scar. It should be noted that in many patients with the 
above-mentioned clinical and instrumental characteristics, 
dyspnea is often equivalent to angina, making it difficult to 
determine treatment priorities. Although the best survival 
prospects for patients with viable myocardium have been 
convincingly proven, so far no direct evidence has yet been 
obtained of the role of viability assessment for choosing be-
tween drug therapy and surgical revascularization [6].
CABG compared to medical  
treatment therapy
The results of many studies indicate the possibility of 
improving the long-term survival of patients with CAD 
and LVD after surgical revascularization compared with 
drug therapy [13, 36]. In 1994, Yusuf et al. carried out a cu-
mulative analysis of data from seven largest studies of that 
time, comparing the effects of CABG and drug therapy on 
10-year survival (n = 2650).  More than 50% of patients 
were diagnosed with a three-vascular lesion of the coro-
nary arteries. In CABG group, a positive effect on survival 
and symptoms was observed compared with drug therapy: 
mortality over 10 years was 26.4 and 30.5%, respectively 
(p = 0.03). Ultimate benefit of surgical revascularization 
was the greatest in patients with LVD, with the mortality 
rate almost halved [38].
It should be noted that in the first revascularization 
studies, patients from the comparison group could not re-
ceive a number of modern medicines. At that time, statins 
and blockers of the renin-angiotensin system were not yet 
available; other agents with proven beneficial prognostic 
effects, such as antiplatelet agents, beta-blockers and min-
eralocorticoid receptor antagonists, have not been used 
routinely. Of course, this feature somewhat limits the possi-
bility of extrapolating the data to the current population of 
patients with CAD and LVD. However, from the standpoint 
of evidence-based medicine, new convincing evidence has 
recently emerged in favor of CABG in patients with LVD 
who received optimal drug therapy [31, 36].
In a surgical treatment for ischemic heart (STICH) 
study 1212 patients with CAD and LVEF ≤35% (mean 
LVEF ratio of 27%) were randomized into CABG groups 
and optimal drug therapy. After 5 years, the frequency of 
death cases from all causes did not differ in the compared 
groups. At the same time, the analysis of a number of se-
condary efficacy criteria (death from all causes or hospita-
lization due to HF, death from all causes or hospitalization 
due to cardiovascular reasons, death from all causes, or 
the need for revascularization) showed the best results in 
the CABG group [36]. The results of a 10-year STICHES 
observation showed an ultimate increase in the life expec-
tancy of patients after CABG by 1.44 years (7.73 versus 6.29 
years, respectively). The results obtained present a convinc-
ing argument in favor of the implementation of CABG in 
patients with CAD and LVD [37].
The STICH study revealed a clear dependence of pa-
tients’ survival on the volume of viable myocardium. Re-
tained viability testified in general to the better prospects 
for survival both after CABG surgery and in the presence of 
drug therapy, but was not a specific indicator of the poten-
tial benefits of surgical revascularization [6]. Obviously, the 
inconsistency of the data obtained was due to the relatively 
small number of cardiovascular events in the compared 
groups and the lack of a unified methodology for determin-
ing the viability of the myocardium. In general, the assess-
ment of viability can be considered in a modern clinic as an 
additional criterion for predicting the results of CABG in 
patients with initially reduced LV pump function [4].
CABG in comparison with the stentation  
of coronary arteries
From the standpoint of evidence-based medicine, the 
results of surgical revascularization compared with coro-
nary artery stenting in patients with CAD and LVD were 
compared in a small number of randomized studies, as well 
as retrospective observations. In a meta-analysis of 19 stu-
dies involving 4766 patients with LVEF less than 40% who 
underwent percutaneous interventions, hospital and an-
nual mortality rates after stenting did not differ from those 
in CABG studies [21]. In another study, no significant dif-
ferences were found in the survival of patients with CAD 
and LVD (LVEF less than 35% in 446 patients) after sten-
ting and CABG with 36-month follow-up (72% vs. 69%, 
respectively) [32]. In a HEART study, stenting or CABG 
was performed in patients with ischemic LVD and viable 
myocardium. After 4 years no difference was found in the 
compared groups either in mortality from all causes, or in 
indicators of the quality of patients’ life. At the same time, 
the study of only 138 patients was not powerful enough to 
assess the differences between groups in terms of their im-
pact on the endpoints. [8]. The advantages of CABG com-
pared with coronary artery stenting in patients with LVD 
are identified during the long-term follow-up in studies 
with a large number of patients [5, 18]. At the same time, 
stenting retains its place as a means of improving the qua-
lity of life of patients with the corresponding anatomical 
indications.
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The benefit of CABG is most noticeable in patients with 
more pronounced and complex stenosing lesions of the 
coronary arteries. According to the analysis of a subgroup 
of patients with a “stem” lesion from SYNTAX study, the 
difference in treatment results in favor of CABG compared 
with stenting was evident in patients with moderate or se-
vere coronary lesions determined by the SYNTAX scale 
[16]. In the FREEDOM study, the beneficial effect of CABG 
on survival was proven in patients with diabetes mellitus, 
who often have diffuse coronary artery lesion [10]. There-
fore, concomitant diabetes mellitus in patients with two or 
more coronary arteries lesions (including those with CAD 
and reduced LVEF) is a strong argument in favor of CABG, 
rather than stenting [25]. 
Revascularization in consensus guidelines
First of all, in the European guidelines for the diagno-
sis and treatment of HF, indications are given for CVG in 
patients with HF [29]. In particular, CVG is recommended 
for patients with angina pectoris, with myocardial revas-
cularization being potentially possible. In addition, symp-
tomatic ventricular arrhythmias or a postponed episode of 
cardiac arrest with successful resuscitation are indications 
for CVG. CVG should also be considered in patients with 
HF and moderate or high pretest likelihood of CAD and 
evidence of ischemia when performing non-invasive stress 
tests.
In patients with stable CAD, the decision to perform 
revascularization is based on angiographic and clinical cri-
teria, and the goal of revascularization is to improve the 
prognosis of survival and / or their quality of life [26]. Both 
of these tasks are undoubtedly relevant for patients with 
LVD of ischemic etiology. It is important to take into ac-
count the absence of LVEF lower threshold when assessing 
the feasibility of revascularization. Moreover, improvement 
in the prognosis and the course of disease after CABG is 
most pronounced in patients with ischemic LVD.
When choosing the optimal method of revasculariza-
tion, it is necessary to consider not only the severity of ath-
erosclerosis of the subepicardial coronary arteries, but also 
the state of the distal bed, as well as the collateral blood 
flow. Ischemic LVD is often accompanied by a multivessel 
lesion, and LVEF decreases with the increase of the total 
lesion of the coronary bed [1]. According to the European 
guidelines [26], CABG surgery is indicated for patients 
with stenosis of the left coronary arterial trunk, three-vas-
cular lesion or a two-vascular lesion, including the anterior 
descending artery, taking into account the severity of the 
lesion of the coronary bed on the SYNTAX scale. Based 
on the results of the STICH study (which did not include 
patients with stem lesions and III-IV functional classes an-
gina), CABG was recommended for patients with HF and 
LVEF ≤35%, lesion of the left anterior descending artery or 
a multivessel lesion, to reduce mortality and hospitaliza-
tions from cardiovascular causes [29]. LVD is a convincing 
additional argument in favor of performing CABG surgery 
in the presence of the corresponding changes in the anato-
my of the coronary bed and clinical symptoms, since it is in 
the category of patients with reduced LVEF that the most 
convincing evidence of the beneficial effect of revascula-
rization on survival is obtained [14, 17, 28, 38].
The American guidelines for CABG also indicate that 
the presence and severity of LVD is one of the clinical fac-
tors influencing the choice of the optimal method of re-
vascularization. According to their authors, the existing 
evidence base has certain limitations, especially in patients 
with severe LVD, but the data on the effectiveness of CABG 
are more convincing compared to stenting. Clinical param-
eters, such as anatomy of the coronary arteries, the pre-
sence of concomitant diabetes mellitus or chronic kidney 
disease, as well as the opinion of the patient, are impor-
tant for choosing a management strategy for patients with 
coronary heart disease and LVD. The final decision is made 
jointly by an interventional cardiologist and a heart sur-
geon [17].
In some special cases of a pronounced decrease in LVEF, 
the final decision on the feasibility of CABG can be made 
taking into account the assessment of myocardial viability. 
In particular, the absence of conclusive evidence of recur-
rent ischemia combined with a small number of viable 
myocardium is considered an argument against the surgi-
cal treatment. In general, the criteria for the selection of 
patients for revascularization depending on the state of via-
bility of the cardiac muscle are still not clearly defined due 
to the lack of evidence base and the lack of a consistent re-
search methodology. It should be also noted that in patients 
with terminal HF, heart transplantation may be considered.
Revascularization effectiveness criteria
Unlike randomized studies, where the effect of revas-
cularization is evaluated by endpoints, in clinical practice 
the main criteria for the effectiveness of the intervention 
are changes in the pumping function of the heart and qual-
ity of life, which is primarily determined by clinical symp-
toms. The increase in LVEF, in turn, favorably influences 
the course and prognosis of the disease [19]. The data of 
most studies indicate a positive effect of revascularization 
on the global pumping function of the heart and local con-
tractility in the area of functioning shunts in patients with 
LVEF less than 40-30% [3, 33, 34]. Greater growth of LVEF 
was recorded after myocardial revascularization in patients 
with worse initial indices of LVEF [15]. At the same time, 
in patients with initially preserved LVEF, a slight decrease 
in LVEF was observed in the postoperative period [20]. In 
the original study of the authors (n = 111), the median of 
LVEF in 6-12 months after CABG surgery increased from 
35 (quartile 30-39) to 42 (35-45%), on average – by 18.9% 
(5.3 -32.4%) [2]. Moreover, in most cases, the growth of the 
LVEF was not immediately observed, but from the end of 
the first month after the operation. With an increase in the 
duration of postoperative follow-up, the increase in LVEF 
achieved during the first year of observation usually does 
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not continue increasing, and the LVEF indicator comes to 
its plateau [23]. Obviously, there remains the need to study 
the predictors of favorable or negative dynamics of LVEF in 
patients with CAD after CABG surgery.
Another sensitive indicator of the outcome of revascu-
larization intervention is the reduction in clinical symp-
toms and improvement in the quality of life associated with 
health status of patients. This aspect in patients with ISHD 
and LVD can be determined not only by LVEF and HF 
functional class according to NYHA classification, but also 
by age, sex and associated diseases. The correct selection of 
patients for surgical revascularization allows us to expect 
an improvement in the quality of life indicators after the 
intervention in the vast majority of patients, this improve-
ment being more tangible than in the presence of drug 
therapy [24]. Stenting of the coronary arteries has advan-
tages in influencing the quality of life soon after the inter-
vention, while the advantages of CABG become apparent 
6-12 months after the operation.
Conclusions
Coronary atherosclerosis is the most common cause of 
a decrease in LVEF and the occurrence of HF in the mod-
ern world. In patients with ischemic LVD, surgical revas-
cularization can ensure an improvement in the pumping 
function of the heart, provided there is a sufficient amount 
of viable myocardium. From the standpoint of evidence-
based medicine, the effectiveness of CABG surgery in pa-
tients with multivessel lesion of the coronary bed and LVD 
has been proven for correction LVEF, improvement of the 
course of the disease and prediction of survival compared 
with the optimal drug therapy. Percutaneous intervention 
is inferior to surgical revascularization in terms of its ef-
fect on endpoints, but it can make an improvement in the 
quality of life of patients with ischemic LVD. Evaluation of 
myocardial viability may be of additional importance for 
the decision on the feasibility of CABG in the presence of 
multivessel coronary artery disease combined with a sharp 
decrease in LVEF.
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